GLP-1 advertising sits where three sets of rules overlap: platform limits on prescription drugs, platform limits on weight-loss ads, and federal scrutiny of health claims and compounded drugs. Clinics feel the pull because patients are searching: "tirzepatide near me" gets 12,100 searches a month at $24.31 a click and "semaglutide near me" 8,100 at $30.19. On the business side, "glp-1 advertising" draws 480 searches, "semaglutide marketing" 70 and "glp-1 marketing" 40 at $75.19 a click (Google Ads Keyword Planner data via DataForSEO, US, 12-month average to Sep 2026). Here is each rule from its official source, as read October 22–23, 2026, and copy that promotes your program without tripping them.
Why GLP-1 ads are a restricted category
Semaglutide (sold as Ozempic, Wegovy and Wegovy HD) and tirzepatide (Mounjaro and Zepbound) are prescription injections (MedlinePlus, semaglutide (opens in a new tab); MedlinePlus, tirzepatide (opens in a new tab)). That one fact pulls a GLP-1 ad into four rulebooks:
| Rule | Why it applies | Section |
|---|---|---|
| Google's prescription drug and prescribing policies | Drug names, online prescribing | Google Ads |
| Meta's Drugs and Pharmaceuticals and Health and Wellness policies | Prescription drug promotion, weight-loss ads | Meta |
| FDA statements on compounded GLP-1 drugs | Compounded products marketed as equivalent | Compounded drugs |
| FTC Act and FTC guidance | Weight-loss and health claims, testimonials | FTC |
A weight program that happens to include medication is easier to advertise than the medication itself. That distinction runs through every section below.
Google Ads: prescription-drug terms and certification
Google's Restricted drug terms (opens in a new tab) policy treats prescription drug names in ads, landing pages and keywords as restricted. For campaigns in the United States, Canada or New Zealand, advertisers "may use prescription drug terms for promotional purposes, in accordance with local laws and regulations," and don't need certification to use them in ads and landing pages, but "must be certified in order to keyword-target these terms."
Separately, Prescription drug services (opens in a new tab) covers "services related to the online prescribing, dispensing, and sale of prescription drugs." A clinic that prescribes GLP-1s through video visits or ships medication is a telemedicine provider in Google's eyes. In the US that means LegitScript or NABP accreditation plus Google certification; in Canada, telemedicine needs LegitScript (Healthcare and medicines (opens in a new tab)). Prescribing without a prescription is treated as an egregious violation that can suspend the account without warning.
Two more Google limits matter here:
- No remarketing. Google's Health category (opens in a new tab) covers conditions and injections, and advertisers in it can't use remarketing lists, Customer Match or lookalikes.
- Canada's drug-ad law. The Food and Drug Regulations limit a public prescription drug ad to "the brand name, the proper name, the common name and the price and quantity of the drug" (C.01.044 (opens in a new tab)).
The fuller walkthrough of statuses and appeals is in Google's healthcare ad policy.
Meta: weight-loss and prescription-drug rules
Meta's Health and Wellness (opens in a new tab) policy (latest change-log entry Jul 22, 2026) applies to every weight-loss ad:
- target people 18 or older;
- no negative statements or questions about appearance or body parts;
- no close-ups of pinched fat;
- no "promises of specific outcomes within a set timeframe without disclaimers or qualifiers."
The same page sends "prescription weight loss products" to the Drugs and Pharmaceuticals (opens in a new tab) policy. There, online pharmacies and telehealth providers must be "actively certified with LegitScript" and then obtain Meta's authorization; ads may target only the United States, Canada or New Zealand and only people 18 or older. Meta also says advertisers don't need written authorization to educate about prescription drugs or to "promote telehealth services generally."
So a med spa can usually run "medical weight management" ads for adults, but an ad that promotes semaglutide itself needs the certification route. Wording patterns that pass are in Meta's health ad rules.
Compounded semaglutide and tirzepatide: claims to avoid
FDA's page on unapproved GLP-1 drugs (content current as of October 1, 2026) is direct: "compounded drugs are not FDA approved," and FDA "does not review compounded drugs for safety, effectiveness or quality before they are marketed" (FDA (opens in a new tab)).
FDA's list of red flags for consumers reads like a list of ad claims to avoid. It warns about companies that:
- make "claims such as the compounded drug is the same as an FDA-approved drug";
- offer "deep discounts or prices that seem too good to be true";
- do "not require a screening and prescription by a licensed doctor."
FDA also reports adverse events linked to dosing errors with compounded injectable semaglutide, and it has sent warning letters to telehealth companies marketing unapproved drugs such as retatrutide.
If your clinic prescribes a compounded product, three claims are off the table: that it's FDA approved, that it's the same as a brand-name drug, and that patients can get it without a medical screening. Using "Ozempic" or "Wegovy" to sell a compounded product implies sameness even if you never say it.
FTC rules on weight-loss and health claims
The FTC's Health Products Compliance Guidance (opens in a new tab) (December 2022) requires health claims to be backed by "competent and reliable scientific evidence," which for health benefits generally means randomized, controlled human clinical testing. The FTC judges the ad's overall "net impression," including images, not single phrases. Detail is in FTC health claims guidance.
Three FTC points hit weight-loss ads hardest:
- Evidence has to match the claim. Results from a study of an FDA-approved drug don't automatically support claims for your program, a different dose or a compounded version.
- Testimonials need typical results. The Endorsement Guides use a weight-loss example: an ad with dramatic results "should clearly and conspicuously disclose what they can expect to lose in the depicted circumstances" (16 CFR 255.2 (opens in a new tab)).
- Some claims are red flags on their own. The FTC's 2014 Gut Check (opens in a new tab) guide, written about weight-loss products generally, lists claims such as "causes substantial weight loss for all users" and "causes permanent weight loss even after the consumer stops using product."
Keep efficacy claims out of ad copy entirely. If you describe what a medication is for, use the approved-use language MedlinePlus gives, for example that semaglutide injection is used "to assist with weight loss in certain people who are obese or overweight and have weight-related medical problems."
Copy that promotes the program, not the drug
The safest GLP-1 ad sells what your clinic actually provides: clinician visits, labs, nutrition support, follow-ups and, when appropriate, a prescription. The drug is a clinical decision made in the visit.
Illustrative example. Fictional clinic (Northgate Weight Clinic). Headlines show patterns, not approved ads.
| Non-compliant or high-risk | Problem | Safer headline |
|---|---|---|
| "Ozempic for $199 a Month, Same Medication" | Sameness claim for a compounded product; drug promotion without certification; FDA price red flag | "Medical Weight Management at Northgate Weight Clinic" |
| "Lose 30 lbs in 8 Weeks with Semaglutide" | Outcome by a deadline; efficacy claim needing evidence | "A Doctor-Led Weight Program with Labs and Follow-Ups" |
| "No Doctor Visit Needed, Shipped Today" | Online prescribing without certification; FDA red flag for no screening | "In-Person Weight Loss Consultations with a Licensed Physician" |
| "FDA-Approved Compounded Semaglutide" | False: compounded drugs are not FDA approved | "Ask Our Clinicians Which Treatment Options Fit You" |
| "Tired of Being Overweight?" | Meta personal attributes and negative body framing | "Weight Care for Adults, Evening Appointments Available" (18+) |
Keyword: semaglutide near me (uncertified) | Keyword-targeting a prescription drug term needs certification | Keywords: medical weight loss clinic, weight loss doctor near me |
Medfy's Google Ads and Meta ads + AI creatives add-ons ($199/month each) write ad copy for healthcare ad policies, and the Google add-on's copy suggestions are policy-checked before you approve them. Medfy doesn't provide LegitScript certification, and it can only run campaigns your accounts are eligible for. For the wider program, see weight loss clinic marketing and med spa advertising. To see what your current ads and landing pages say, run a free marketing audit; the full rule map is at medical advertising regulations.
This is general information, not legal advice. Confirm how it applies to your practice with a qualified advisor.
Frequently asked questions
Can I advertise semaglutide on Google?
Partly. For US and Canadian campaigns, Google allows prescription drug terms in ad text and landing pages under local law, but you must be certified to bid on them as keywords, and online prescribing needs LegitScript or NABP accreditation plus Google certification. An in-person clinic can advertise its weight program without naming the drug in keywords. Canadian law also limits what a public drug ad may say.
Can med spas run GLP-1 ads on Facebook?
They can advertise a medical weight program to adults 18 and older, following Meta's weight-loss rules. Promoting the drug itself is different: Meta routes prescription weight-loss products to its Drugs and Pharmaceuticals policy, which requires LegitScript certification for telehealth providers and pharmacies, Meta's authorization, and targeting limited to the US, Canada or New Zealand.
Can I mention Ozempic by name in my clinic's ads?
Be careful. Google requires certification to keyword-target prescription drug names, Meta requires certification and authorization to promote prescription drugs, and if you prescribe compounded semaglutide, naming a brand can imply your product is the same drug, which FDA flags as a warning sign. Most clinics are safer promoting the program and the clinician, not the brand.
What weight-loss claims can a clinic make?
Only claims you can back with competent and reliable scientific evidence that matches what you're promoting, under the FTC's Health Products Compliance Guidance. Avoid pound counts, deadlines and promised results in ads. If you show a patient's results, the FTC expects you to state what patients generally achieve, and HIPAA requires the patient's written authorization first.